Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): evaluation report

01 Pre-Meeting Briefing prepared by NICE

02 Submission from the technology manufacturer Roche Products

03  NICE request to the manufacturer for clarification on their submission

04 Manufacturer clarification response

05 Consultee submission - British Association of Dermatologists

06 Consultee submission - British Association for Paediatric Nephrology

07 Consultee submission - British Society for Paediatric and Adolescent Rheumatology

08 Consultee submission - British Society for Rheumatology

09 Consultee submission - Royal College of Nursing

10 Consultee submission - Vasculitis UK

11 Consultee submission – UKVAS

12 Clinical expert personal perspective – Harper

13  Clinical expert personal declaration – Lanyon

14 Patient expert personal declaration – Mills

15 Patient expert personal perspective – Ranyell

16 Evidence Review Group Report prepared by School of Health and Related Research (ScHARR)

17 Evidence Review Group Report Erratum

18 Manufacturer factual accuracy check of Evidence Review Group report


Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 22 July 2013